PF-08052667 / Pfizer - LARVOL DELTA

Enhanced delivery and activity of a novel antibody-drug conjugate, PF-08052667, for treatment of non-muscle invasive bladder cancer (AACR 2026) - P1 | "Following repeated local administration of PF-08052667 with bladder prewash, systemic exposure remained minimal, and no systemic toxicity was detected. Overall, these findings support the clinical development of PF-08052667 with bladder prewash, which is being evaluated for safety and antitumor efficacy in a Phase I trial (NCT07206225) involving patients with NMIBC."

ADC • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (clinicaltrials.gov) - P1 | N=294 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

PF-08052667: An antibody-drug conjugate optimized for intravesical delivery to treat non-muscle-invasive bladder cancer (ESMO 2025) - "PF-08052667 targets IB6 with the same antibody backbone as sigvotatug vedotin. The PF-08052667 design and functional data support its clinical development to evaluate its safety and anti-tumor activity in a phase I first-in-human study. Legal entity responsible for the study Pfizer Inc."

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (clinicaltrials.gov) - P1 | N=294 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor